Drug Profile
Parathyroid hormone (1-34) cyclised - Roche
Latest Information Update: 31 Jan 2007
Price :
$50
*
At a glance
- Originator Roche
- Class
- Mechanism of Action Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 17 Jan 2001 No-Development-Reported for Postmenopausal osteoporosis in Germany (Parenteral)
- 26 Mar 1998 Phase-II clinical trials for Postmenopausal osteoporosis in Germany (Parenteral)
- 11 Jul 1997 Preclinical development for Postmenopausal osteoporosis in Germany (Parenteral)